L’Oreal Falls Short On Safety, Efficacy, Adverse Event Data
This article was originally published in The Tan Sheet
Executive Summary
FDA says it needs additional data from L’Oreal on safety, efficacy and adverse events to determine GRASE for drometrizole trisiloxane.
You may also be interested in...
FDA Deems UVA Filter Ecamsule Eligible For Monograph Inclusion, Seeks Data
FDA's recent decision that the breakthrough UVA filtering ingredient ecamsule is eligible for inclusion in the OTC sunscreen drug monograph pending a safety and efficacy evaluation could level the playing field among competing manufacturers in the U.S. and offer innovators more flexibility
Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024
Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.
Regulatory Acceptance Of Non-Animal Test Methods Holding Back Cosmetics Innovation
“Companies can innovate right now, and they have confidence in these tools, these [non-animal] approaches, and they feel they can put these products on the market safely,” said Erin Hill, CEO and president of the International Collaboration on Cosmetics Safety. “The holdup is that they can’t register these new products, because there’s a lack of confidence in the regulatory community.”